Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07309952) titled 'Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Yang Hong
Condition:
Locally Advanced Non-Small Cell Lung Cancer
Stage IIIb Non-small Cell Lung Cancer
Stage IIIC Non-Small Cell Lung Cancer
Intervention:
Drug: Sintilimab
Drug: Paclitaxel
Drug: Carboplatin (AUC 5)
Drug: Pemetrexed 500 mg/m2
Radiation: Stereotactic body radiotherapy (SBRT)
Recruitment Status: Not recruiting
Phase: Phase 2...